Abstract 183P
Background
In cancer, inflammation frequently coexists with hypoxia within the tumor microenvironment (TME), often creating an immunosuppressive environment. This hostile milieu is further exacerbated by acidosis, which collectively further hinders effective anti-tumor immune responses. Carbonic anhydrase IX (CAIX) is a well-established hypoxia marker that plays a key role in the pH regulation and adaptation of tumor cells to hypoxia resulting in tumor progression. The CAIX activity contributes to the formation of an acidic environment, which can suppress the function of cytotoxic T cells and other immune cells. While primarily induced by HIF1α under hypoxic conditions, CAIX expression can also be triggered in an inflammatory milieu by IL6 or the COX-2/PGE2 pathway. The goal of this study is to determine the role of CAIX in the regulation of inflammatory and anti-tumor immune responses.
Methods
CAIX+ and CAIX-silenced HT1080 cells were cultured in the presence of a conditioned (inflammatory) medium obtained from MUF spheroids (MUF-CM) under normoxic or hypoxic conditions. RNA samples were analyzed by Clariom, followed by unsupervised clustering. Gene Set Expression Analysis (GSEA) was used to analyze the gene expression. The relation between CAIX level and gene sets identified by GSEA was also analyzed in TCGA SARComa samples and pancreatic cancer (PC).
Results
We found that MUF-CM can upregulate CAIX expression in fibrosarcoma and PC cells even under normoxia. Our analysis revealed that suppression of CAIX leads to upregulation of hallmarks of IFN-α, IFN-γ, and inflammatory response. In silico analysis of TCGA SARC samples confirmed the relationship between lower CAIX expression and higher expression of IFN-α, IFN-γ and inflammation response gene sets, which predicted better overall survival. Moreover, the immune gene sets associated with immune activation and expression of HLA-antigens negatively correlated with CAIX.
Conclusions
Understanding the complex interplay between hypoxia, CAIX, and inflammation is crucial for developing effective cancer treatments. Given the central role of CAIX in this intricate relationship, targeting the function of this enzyme may represent a new opportunity to create a favorable milieu for anti-tumor immune response in the TME.
Legal entity responsible for the study
The authors.
Funding
The Slovak Research and Development Agency 20-0480.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract